Kornimate/medical-research-clean huggingface dataset:
measuring work-related stress in primary care in the covid-19 pandemic

Conditions: Occupational Stress; Covid19

Summary: this prospective cohort study was designed to assess wrs amongst clinical and non-clinical staff in a primary healthcare setting using a validated tool with a view to developing an evidence base to form a historical and comparative record during the covid-19 pandemic.

work-related stress (wrs) is the second most common cause of occupational ill health in the united kingdom. studies suggest that during the covid-19 pandemic, an increased prevalence of stress-related disorders was reported amongst healthcare workers. wrs can be assessed using the health and safety executive's (hse) management standards indicator tool (msit) and is used to compare changes to wrs across six domains over time. lower scores in domains indicate higher wrs experienced by workers. increases in the score in subsequent assessments indicate improvements to wrs. the msit was distributed to 23 primary care clinical and non-clinical staff in a medical centre in greater manchester, united kingdom in march, 2019. 18 responses were received from 23 staff (78% response rate), establishing a baseline. in may, 2020, the authors decided to reanalyse the effect of the covid-19 pandemic on wrs upon the same population. the msit was redistributed in march 2021, with 14 responses from 20 staff (70% response rate). microsoft excel's data analysis was applied to the results. wrs across the practice increased by 7% in demands, 4% in control and 2% in role domains and improved by 3% in support, 3% in relationships and 2% in change domains. the results are in keeping with the global picture of evolving wrs amongst healthcare staff during the pandemic. monitoring and addressing wrs regularly helps maintain system-wide resilience when faced with unexpected or unprecedented change. comparing these results with wrs in other healthcare systems would be a useful next step.

Eligibility criteria:
inclusion criteria: * primary healthcare staff working at the gill medical centre for at least two months prior to assessment. exclusion criteria: * any staff member employed for less than two months, those who were off work due to non- stress related long-term leave or incomplete submissions.

Keywords: pandemics primary health care
polestriding versus walking for subjects with poor leg circulation

Conditions: Peripheral Arterial Disease

Summary: the purpose of this study is to compare the effects of polestriding (walking with poles) and traditional walking on physical endurance in subjects with poor circulation in their legs. another goal is to evaluate the effectiveness of a walking program in increasing the amount of oxygen in the calf muscles and therefore improving overall physical activity and quality of life.

peripheral arterial disease (pad/pvd) is caused by decreased blood flow to the legs. the most common symptom is intermittent claudication pain during walking that is relieved by rest. walking is the primary treatment prescribed for pad rehabilitation. polestriding uses muscles of the upper and lower body in a continuous movement. walking with poles increases stride length, cadence and walking speed and decreases ground reaction forces on the joints. subjects in this study will participate in a walking program with or without poles. dr. collins' research focuses on physical activity interventions to improve the functional status of persons with chronic illness. several rehabilitation studies have tested the efficacy of walking exercise for patients with pad. studies on polestriding indicate that it may be superior to traditional walking, but these two methods have never been compared. approximately 30% of patients with coronary artery disease have pad as their only symptom. as the population ages and more people are affected by this debilitating condition, nurse-initiated rehabilitative therapies, such as polestriding, need to be explored. the consent form explains the purpose of the study in addition to the procedures, risks, benefits, options, confidentiality, costs, and compensation. participants are also asked to sign a hippa authorization.

Eligibility criteria:
inclusion criteria: * peripheral vascular disease * cramping/claudication pain in legs while walking * ankle brachial index (measure of circulation by doppler) .90 or less exclusion criteria: * ulcers or sores on feet or legs * unable to walk or confined to a wheelchair * amputations or severe arthritis pain in shoulders, knees, or hips * medical conditions which would exclude subject from participating in an exercise program * vascular surgery within the last six months, or planning vascular surgery
evaluating the relationship between hard and soft tissue advancement in orthognathic surgery

Conditions: Dentofacial Deformities

Summary: this study aims to evaluate the relationship between hard and soft tissue advancement during orthognathic surgery. the use of typical pre and post operative imaging consisting of con-beam computed tomography will be used, in conjunction with a 3d camera to evaluate hard and soft tissue points before and after surgery.


Eligibility criteria:
inclusion criteria: * patient's undergoing orthognathic surgery for correction of a dentofacial deformity exclusion criteria: * patients with previous orthognathic surgery patients with cranio-facial syndromes
the association of gut microbiota with covid 19 infection in children

Conditions: Coronavirus Infections; Gut Microbiome; Childhood ALL

Summary: although covid-19 infects gastrointestinal tissues, little is known about the roles of gut commensal microbes in susceptibility to and severity of infection. the investigators will analyze the alterations in fecal microbiomes of patients with covid-19 infection during hospitalization.


Eligibility criteria:
inclusion criteria: * patients infected with covid 19 exclusion criteria: * congenital heart, renal, intestinal disease * malignancy * immunologic disease
pilot study with a diffractive trifocal iol (pod ay 26p finevision)

Conditions: Bilateral Cataract

Summary: the principal objective of the study is to determine the visual acuity at far, intermediate and near distances tested with optotypes at different distances from the eyes and tested with defocus addition lenses of patients implanted bilaterally with the pod 26p ay finevision. secondary objective will be to test the glare and contrast sensitivity.

this study is a pilot study. as such it will recruit a limited number of patients : 20. patients recruited will suffer from cataract, have no comorbidity, expressed the desire for spectacle independence and have realistic expectations. descriptive statistics will be used to determine the visual acuities at any distance. the occurence of glare and the determination of the contrast sensitivity will also be determined.

Eligibility criteria:
inclusion criteria: * - age-related cataract * preoperative corneal astigmatism \< 0.75 d * age 21 and older * visual acuity \> 0.05 * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant. * patient willing multifocal implantation and with realistic expectations. exclusion criteria: * relevant other ophthalmic diseases such as pseudoexfoliation syndrome, floppy iris syndrome, corneal pathologies, retinal pathology (diabetic maculopathy, myopic maculopathy, age related macular degeneration...) * previous ocular surgery or trauma.

Keywords: cataract iol trifocal finevision
a randomized, double masked, parallel group, dose-finding study to evaluate syl1801 in patients with neovascular age-related macular degeneration (amd)

Conditions: Wet Macular Degeneration; Neovascular Age-related Macular Degeneration; Macular Degeneration

Summary: the goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of syl1801 eye drops.


Eligibility criteria:
inclusion criteria: * signed informed consent * active subfoveal or juxtafoveal choroidal neovascularization secondary to amd * best corrected visual acuity (bcva) between 70-25 letters (etdrs) at screening * intraretinal or subretinal fluid * central subfield thickness \> 300 µm exclusion criteria: * pregnant or breastfeeding females or those with a positive pregnancy test. * females of childbearing potential who will not use a medically acceptable contraceptive method * current, previous chronic or recurrent condition according to the investigator's judgement. * concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications * concurrent disease in the study eye * previous treatment with systemic anti-vascular endothelial growing factor (anti-vegf) drugs or pro-vegf treatments * concurrent disease in the study eye, other than amd

Keywords: sirna oligonucleotide
nutritional strategy for glycemic control in patients with type 2 diabetes mellitus (nuglic)

Conditions: Diabetes Mellitus, Type 2

Summary: adherence to a healthy dietary pattern is part of the self-care of patients with type 2 diabetes mellitus (t2dm), and may contribute substantially to therapeutic target goals and to a better quality of life as well. however, not all nutritional recommendations aimed at these patients are easily applicable in clinical practice. the primary objective of the study is to evaluate the effectiveness of a nutritional strategy for glycemic control in patients with t2dm users of a public health system after 6 months of follow-up. as secondary objectives, we will evaluate the impact of the proposed strategy on self-care and on the quality of life of the patients. in this randomized multicenter open-label randomized trial, 370 patients \>30 years old with t2dm, glycated hemoglobin (hba1c) ≥7% at the moment of the screening and who have not received or received nutritional counseling for at least 06 months will be enrolled. patients allocated to the control group will receive individualized dietary prescription according to the guidelines of the brazilian society of diabetes. nutritional counseling in the intervention group will be performed based on the quality of the diet, the food guide for the brazilian population and concepts of mindfulness and mindful eating; all dietary guidance will be based on feasible goals built together (patient and nutritionist), and no diet will be prescribed for intervention group. in both groups, patients will receive glymeters for residential self-monitoring of glycemic levels. on-site follow-up visits will be carried out at 30, 60, 90, and 180 days (final consultation). at 120 and 150 days, participants in the intervention group will receive motivational messages via e-mail or sms (for these patients, consultation of 30 days will be a group meeting). laboratory tests (lipid and glycemic profile, serum creatinine, serum sodium, urinary sodium, serum potassium, urinary potassium and albuminuria) will be performed at baseline and 180 days; anthropometric indexes and blood pressure will be also evaluated.


Eligibility criteria:
inclusion criteria: \>30 years old with medical diagnosis of t2dm, glycated hemoglobin (hba1c) ≥7% at the moment of the screening and who have not received or received nutritional counseling for at least 06 months. exclusion criteria: * patients with type 1 dm (t1dm), latent autoimmune diabetes in adults (lada) or hba1c ≥ 12%; * severe neuropathy; * chronic kidney disease; * active cancer or life expectancy \<6 months; * chemical dependence or use of antipsychotic drugs; * autoimmune disease or chronic use of steroids; * gastroparesis; * pregnancy, lactation, gestational dm; * acute coronary syndrome (acs) in the last 60 days; * wheelchair users; * extreme obesity (body mass index \[bmi\] ≥40kg/m²); * cognitive, neurological or psychiatric condition that prevents participation in the study; * participation in other clinical trials.
influence of osteoarthritis information on treatment beliefs

Conditions: Osteoarthritis, Knee

Summary: the aim of this study is to evaluate the effect of educational information, with and without a general practitioner recommendation to exercise, on willingness to undertake exercise/physical activity for knee osteoarthritis. eligible participants will be aged 45+ years and will not currently have osteoarthritis, knee pain, or any condition that makes them unable to exercise. participants will be asked to complete an online survey, during which they will be randomised to one of three groups and shown different types of educational information to read. outcome measures will be collected as part of the survey before and after participants read the educational information presented to them.

3-arm superiority online randomised controlled trial (delivered within one survey). participants will complete an online survey, during which they will be presented with a hypothetical scenario asking them to imagine that they had recently developed knee pain and have gone to see their general practitioner. participants will then be randomised to one of 3 different groups (described below). each group will be shown different types of educational material and asked to read the information carefully. once they have finished reading the material, they will be asked to complete follow-up outcome measures to determine whether their beliefs about osteoarthritis management strategies have changed. the 3 trial groups are: i. control group: asked to read a single-a4 page of brief osteoarthritis information ("what is osteoarthritis"); ii. treatment options group: asked to read brief osteoarthritis information + two a4 pages of information on treatment options ("osteoarthritis treatment options"), and; iii. treatment options + recommendation group: asked to read brief osteoarthritis information + information on treatment options + receive a hypothetical gp recommendation for exercise

Eligibility criteria:
inclusion criteria: * aged 45+ years exclusion criteria: * been told by a health professional that they have osteoarthritis in any joint/anywhere in the body * have experienced any knee pain in the prior 3 months * unable to read english * have had a joint replacement in any knee or hip joint * have any health condition that makes unable to exercise

Keywords: osteoarthritis knee education decision aid beliefs
the norwegian tick-borne encephalitis study

Conditions: Tick-Borne Encephalitis, European

Summary: during 2018, 2019, and 2020, the reported tbe-cases have increased markedly in norway. surveillance studies conducted by the norwegian institute of public health demonstrate that cases are associated with tick bites in the coastal areas of the agder, buskerud, and vestfold and telemark counties there is a urgent need for more knowledge of the consequences of tbe in norway, in particular the identification of patients at risk of long-term sequela. hence, the overall objective of this project is to gain more knowledge about the natural course of tbe in norway, and its impact on long-term health-related quality of life and associated factors. clinical data, biological sampling and proms are collected from tbe-infected patients admitted to three hospitals within the epidemic region in norway.

this project is designed as a multicenter study divided into four sub-studies: substudy 1: a retrospective descriptive study of the clinical features and objective findings of the acute phase of the tbe-patients diagnosed with tbe in south-east norway during 2018, 2019 and 2020. substudy 2: a prospective multicenter study of health related qol one year after hospitalization with tbe in south-east norway from 2019 - 2023. the self-reported health-related qol (assesedby sf-36) of the tbe-patients will be compared with the sf-36 reference values in the norwegian population. substudy 3: a prospective multicenter study of self-reported cognitive function one year after hospitalization with tbe in south-east norway from 2019- 2023. the cognitive function, measured by proms, will be compared with proms from an included reference group from the patient's social environment. substudy 4: analyses of biological samples collected at baseline, 3 months and 12 months after hospitalization for tbe in patients included in substudy 2 and 3. these analyses will be conducted to gain more knowledge of the pathogenesis of tbe infection and in particular, which molecular pathways and biomarkers that characterize the tbe infected patients who are hospitalized in norway. analyses to identify associations between the acute inflammatory response and long-term outcome will be performed.

Eligibility criteria:
inclusion criteria: 1. patient: the patients diagnosed with acute infection with tbev at admission. 2. control: same age (plus/minus 4 years), level of education (plus minus 2 years) and the same gender as patient. exclusion criteria: 1. patient: patients who turn out to have different diagnose than acute infections with tbev. 2. control: previously infection with tick-borne encephalitis virus. 3. the patients who were diagnosed with typical symptoms and only tbev igm-test must take a blood sample for igg analyses. if the tbe igg analysis is negative, the patient will be excluded.
a study of shr-1702 alone or with camrelizumab in participants with advanced relapsed/refractory solid tumors

Conditions: Advanced Solid Tumor

Summary: the purpose of this study is to evaluate the safety of shr-1702 monotherapy or in combination with camrelizumab among advanced solid tumor subjects.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed advanced relapsed/refractory solid tumors * must have a performance status of 0 to 1 on the eastern cooperative oncology group (ecog) scale * have an estimated life expectancy of 12 weeks, in judgement of the investigator； * must have at least 1 measurable lesion assessable using standard techniques by response evaluation criteria in solid tumors version 1.1 (recist 1.1) * adequate hematologic and organ function * signed inform consent form exclusion criteria: * history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest ct scan. * significant cardiovascular disease * uncontrolled pleural effusion, pericardial effusion, or ascites requiring * history of autoimmune disease. * subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. inhaled or topical steroids, and adrenal replacement steroid are permitted in the absence of active autoimmune disease. * positive test result for human immunodeficiency virus (hiv); active hepatitis b or hepatitis c * active or untreated central nervous system (cns) metastases * active infection within 2 weeks * history of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins * prior allogeneic bone marrow transplantation or solid organ transplant * history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
recurrent crying spells in cerebral palsy

Conditions: Recurrent Crying Spells

Summary: this is a study of recurrent crying spells in spastic cerebral palsy patients and their treatment.

this is the first study of recurrent crying spells in cerebral palsy with spastic quadriparesis depicting the diagnostic criteria and treatment.

Eligibility criteria:
inclusion criteria: * recurrent crying spells in cerebral palsy with spastic quadriparesis. * age range 0-12 years. exclusion criteria: * crying due to known causes (like hunger, sleep, food intolerance etc.), * crying that responded to routine management (changes in food or feeding techniques, anticolic, analgesics), * fever of ≥100.4ºf (38ºc), * the infant refuses to eat or drink for more than a few hours, vomits excessively, has bloody stools, or has a change in behavior (lethargy or decreased responsiveness). * colic * worst ever crying occurring for the first time * respiratory, renal and hepatic diseases, * progressive encephalopathies, * received baclofen in the previous 30 days

Keywords: baclofen cerebral palsy colic crying infant recurrent crying spells spasticity therapy
structural brain abnormalities in children born prematurely: new detection methods and clinical-pathological correlates

Conditions: Infant, Premature; Brain Injuries

Summary: the purpose of the study is to detect structural brain changes using mri and to correlate these findings with neurodevelopmental assessments in two-year old children previously enrolled in the nih sponsored trial of inhaled nitric oxide (ino) for the prevention of chronic lung disease in preterm ventilated infants. it is hypothesized that this imaging will identify children with previously undiagnosed brain abnormalities and that the presence of structural abnormalities will be associated with deficits in motor, cognitive, and neurosensory development.

infants born prematurely are at significant risk for hemorrhagic and ischemic brain injury. despite improved survival rates among this population in recent years, these forms of brain injury remain frequent and have considerable consequences. periventricular leukomalacia (pvl), a disease characterized by necrosis of the cerebral white matter in a characteristic distribution, is one of the most common types of brain injury seen in premature infants. mri technology now allows for better anatomical resolution resulting in improvements in diagnostic accuracy. the current standard practice is not to perform routine mri examinations on premature infants, nor is it routine to perform surveillance brain imaging in children after leaving the nicu. in their 2002 practice parameter for neuroimaging in the neonate, the american academy of neurology and the practice committee of the child neurology society acknowledge the superiority of mri in detection of brain lesions in premature infants, but fall short of recommending routine mri scanning on the basis of a lack of information correlating mri findings to neurodevelopmental outcomes. we now have a unique opportunity to help provide such information.

Eligibility criteria:
inclusion criteria: * must be participants in trial (nhlbi-uo1-hl62514-05a1 and fda ind # 58,146 - roberta a ballard pi) of inhaled nitric oxide (ino) for the prevention of chronic lung disease in preterm ventilated infants * gestational age between 24 months and 27 months exclusion criteria: * history of allergy to sedation agents * medical conditions which may pose a threat to airway integrity (i.e., pierre-robin sequence, intercurrent respiratory illness) * other conditions which may otherwise place subjects at increased risk for complications from sedation and mri examination

Keywords: etiology pathology